A Comparison of in vivo Tumor-Homing Abilities of Placental-Derived and Bone Marrow-Derived Mesenchymal Stromal Cells in High-Risk Neuroblastoma

In brief

This study evaluates placental-derived versus bone marrow-derived mesenchymal stromal cells as potential cellular delivery vehicles for treating high-risk neuroblastoma in children. Using an orthotopic xenograft model, researchers compared the tumor-homing capabilities of both MSC types to determine which shows superior targeting for future therapeutic applications.

• Mesenchymal stromal cells possess innate tumor-homing properties that may enable targeted cellular therapy delivery in neuroblastoma
• Placental-derived MSCs and bone marrow-derived MSCs were compared for tumor-homing efficacy in orthotopic neuroblastoma models
• MSC-based delivery vehicles represent a novel therapeutic approach for high-risk neuroblastoma in pediatric patients

Written by the GCMD Library team from the article.